surmount-1 tirzepatide non-diabetic obesity trial Study Finds Individuals with Lost up to 22.5% of their Body Weight when Taking Weight reduction with different doses

Serious but Rare Risks GLP-1 medications can aggravate or trigger severe pancreatic inflammation in some patients. Both oral and injectable GLP-1 medications may cause gallbladder disease, and in rare cases involving patients with relevant risk factors, there have been associations with thyroid changes observed in animal studies. A serious allergic reaction is possible but uncommon

Researchers observed no statistically significant differences between user groups in the risk for cirrhosis complications (18.64 vs

If your insurance is more likely to cover one medication over another, that becomes the practical choice

While Mounjaro and Ozempic are FDA-approved for type 2 diabetes, Zepbound is approved for weight loss only